ETR:SAZ - STADA Arzneimittel Aktiengesellschaft Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: €0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
€80.40
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New STADA Arzneimittel Aktiengesellschaft Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SAZ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SAZ

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
€0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for STADA Arzneimittel Aktiengesellschaft in the last 3 months. The average price target is €0.00, with a high forecast of €0.00 and a low forecast of €10,000,000.00. The average price target represents a -100.00% upside from the last price of €80.40.
N/A
The current consensus among 0 polled investment analysts is to n/a stock in STADA Arzneimittel Aktiengesellschaft. This rating has held steady since August 2019, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
8/10/2018CfraSet Price TargetSell€70.00
i
5/9/2018Independent ResearchSet Price TargetNeutral€89.00
i
5/8/2018CfraSet Price TargetSell€70.00
i
4/4/2018Warburg ResearchSet Price TargetSell€74.40
i
4/4/2018Independent ResearchSet Price TargetNeutral€89.00
i
3/29/2018Independent ResearchSet Price TargetNeutral€89.00
i
3/23/2018Nord/LBSet Price TargetSell€74.40
i
3/21/2018Independent ResearchSet Price TargetNeutral€89.00
i
3/12/2018CfraSet Price TargetSell€70.00
i
3/12/2018Independent ResearchSet Price TargetNeutral€89.00
i
3/9/2018Warburg ResearchSet Price TargetSell€74.40
i
12/26/2017Independent ResearchSet Price TargetNeutral€89.00
i
12/26/2017CommerzbankSet Price TargetSell€66.25
i
12/26/2017Nord/LBSet Price TargetSell€74.40
i
12/20/2017Nord/LBSet Price TargetSell€74.40
i
12/20/2017CommerzbankSet Price TargetSell€66.25
i
12/20/2017Independent ResearchSet Price TargetNeutral€89.00
i
12/20/2017Warburg ResearchSet Price TargetSell€74.40
i
11/29/2017Nord/LBSet Price TargetSell€74.40
i
11/10/2017S&P GlobalSet Price TargetSell€74.40
i
11/10/2017Independent ResearchSet Price TargetNeutral€82.00
i
11/10/2017Warburg ResearchSet Price TargetSell€74.40
i
9/5/2017Independent ResearchSet Price TargetSell€76.00
i
9/5/2017Warburg ResearchSet Price TargetSell€74.40
i
8/31/2017Nord/LBSet Price TargetSell€65.53
i
8/30/2017Warburg ResearchSet Price TargetSell€66.25
i
8/29/2017Independent ResearchSet Price TargetSell€76.00
i
8/22/2017CommerzbankSet Price TargetSell€66.25
i
8/21/2017Independent ResearchSet Price TargetSell€70.00
i
8/18/2017Warburg ResearchSet Price TargetSell€66.25
i
8/16/2017CommerzbankSet Price TargetSell€58.00
i
8/9/2017Independent ResearchSet Price TargetNeutral€66.25
i
8/3/2017S&P GlobalSet Price TargetNeutral€66.25
i
7/11/2017Kepler Capital MarketsSet Price TargetNeutral€66.00
i
7/11/2017S&P GlobalSet Price TargetNeutral€66.25
i
7/11/2017Independent ResearchSet Price TargetNeutral€66.25
i
7/10/2017CommerzbankSet Price TargetNeutral€66.00
i
7/5/2017Warburg ResearchSet Price TargetNeutral€60.00
i
7/4/2017Independent ResearchSet Price TargetNeutral€66.00
i
7/4/2017Kepler Capital MarketsSet Price TargetNeutral€66.00
i
7/3/2017CommerzbankSet Price TargetNeutral€66.00
i
6/28/2017Warburg ResearchSet Price TargetNeutral€60.00
i
6/28/2017S&P GlobalSet Price TargetNeutral€63.00
i
6/28/2017Kepler Capital MarketsSet Price TargetSell€58.00
i
6/27/2017Independent ResearchSet Price TargetSell€50.00
i
6/27/2017CommerzbankSet Price TargetNeutral€66.00
i
6/22/2017Kepler Capital MarketsSet Price TargetSell€62.50
i
6/21/2017Warburg ResearchSet Price TargetSell€66.00
i
6/20/2017CommerzbankSet Price TargetNeutral€66.00
i
6/12/2017Independent ResearchSet Price TargetNeutral€66.00
i
6/8/2017Warburg ResearchSet Price TargetSell€66.00
i
5/29/2017S&P GlobalSet Price TargetNeutral€66.00
i
5/29/2017Independent ResearchSet Price TargetNeutral€66.00
i
5/20/2017S&P GlobalSet Price TargetNeutral€66.00
i
5/20/2017Independent ResearchSet Price TargetNeutral€66.00
i
5/20/2017Warburg ResearchSet Price TargetSell€66.00
i
5/20/2017CommerzbankSet Price TargetNeutral€66.00
i
(Data available from 3/1/2016 forward)
STADA Arzneimittel Aktiengesellschaft logo
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidin Naloxone for pain; Atorvastatin for elevated cholesterol levels; Epoetin zeta for anemia; Diclofenac for pain/inflammation; and Pantoprazole for gastric ulcer/reflux. The Branded Products segment offers APO-Go a Parkinson's medicine; Grippostad a cold medicine; Aqualor for rhinitis/sore throat; Snup for rhinitis; and Vitaprost for prostate disease indications. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and consumers, doctors, pharmacies and pharmacy chains, hospitals, mail-order companies, buying groups, wholesalers, and other service providers in the health care market, as well as public or private health insurance organizations. The company was founded in 1895 and is headquartered in Bad Vilbel, Germany. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH.
Read More

Today's Range

Now: €80.40
€79.56
€80.98

50 Day Range

MA: €80.40
€80.40
€80.40

52 Week Range

Now: €80.40
€53.41
€80.98

Volume

92,068 shs

Average Volume

51,761 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of STADA Arzneimittel Aktiengesellschaft?

The following Wall Street sell-side analysts have issued reports on STADA Arzneimittel Aktiengesellschaft in the last twelve months:
View the latest analyst ratings for SAZ.

What is the current price target for STADA Arzneimittel Aktiengesellschaft?

0 Wall Street analysts have set twelve-month price targets for STADA Arzneimittel Aktiengesellschaft in the last year. has the lowest price target set, forecasting a price of €10,000,000.00 for STADA Arzneimittel Aktiengesellschaft in the next year.
View the latest price targets for SAZ.

What is the current consensus analyst rating for STADA Arzneimittel Aktiengesellschaft?

STADA Arzneimittel Aktiengesellschaft currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SAZ.

What other companies compete with STADA Arzneimittel Aktiengesellschaft?

How do I contact STADA Arzneimittel Aktiengesellschaft's investor relations team?

STADA Arzneimittel Aktiengesellschaft's physical mailing address is Stadastrasse 2-18, BAD VILBEL, 61118, Germany. The company's listed phone number is +49-6101-6030. The official website for STADA Arzneimittel Aktiengesellschaft is www.stada.de.